在养老护理中，排泄问题一直是个"隐秘的顽疾"：护理员忙于无休止的盲目排查，而老人则在"突然失禁"的恐惧中不敢出门、拒绝社交。这种高度依赖人 工经验的模式，不仅让人力成本居高不下，也让老人的尊严感处于被动。 就在大家还盯着"纸尿裤"做文章时，日本公司 Triple W 换了个思路：与其被动"吸"，不如主动去"测"。 它研发出的 DFree，是全球首款能"预知上厕所时间"的可穿戴设备。它 利用医用级超声波传感器监测膀胱变化，帮 B 端养老机构降低了"无效巡视"和"纸 尿裤浪费"；让失禁老人找回了"出门的勇气"和社交的自由。 这种看似"冷门"的刚需，正在全球范围内展现出惊人的商业爆发力。 Triple W 到底通过什么机制，把非标的"生理需求"变成了标准化的生意？它是如何让全球数百家机构买单的？作为"排泄预测"赛道的开创者，它的成功给 中国银发经济带来了哪些关于"尊严经济"的启示？ o1 产品重构：不是监测"尿湿"，而是预防"失禁" 在 DFree 出现之前，排泄护理市场长期停留在"事后处理"阶段：传感器只能在尿湿后报警，护工永远在疲于奔命地补救。 DFree 的核心差异化在于"事前预测"。它不依赖护工的直觉，而是 ...

澜起科技港交所上市 2月9日，澜起科技股份有限公司（06809.HK）成功在香港联合交易所主板挂牌上市，成为全球互连芯片A+H股成功上市企业。 澜起科技是全球仅有的两家能够提供从DDR2到DDR5全系列内存全缓冲/半缓冲完整解决方案的供应商之一，相关市场份额稳居全球前列。澜起电子科技 （珠海横琴）有限公司成立于2024年6月，是澜起科技旗下控股子公司，横琴粤澳深度合作区育苗培优企业，获得第三届横琴国际科技创新创业大赛二等 奖。 自落地合作区以来，澜起横琴以"打造引领全球的CXL芯片总部"为核心目标，全力聚焦CXL芯片的技术研发与产业生态构建。 极物思维冲刺港股IPO 近日，极物思维正式向香港联合交易所主板递交上市申请，标志着公司资本化进程迈入新阶段。 伴随港股IPO筹备工作的深入推进，集团正进一步强化总部功能与区域协同能力，将横琴打造为连接全国门店网络、资本市场与大湾区消费市场的重要枢 纽。 与此同时，极物思维已启动在合作区布局品牌门店的相关筹备工作，探索将总部管理能力、品牌示范效应与本地消费场景深度结合，打造"总部在横琴、 样板在横琴、辐射全国"的发展模式。 真健康四款产品入选 《优秀国产医疗设备目录》 近 ...

Core Viewpoint - The Shanghai Municipal Development and Reform Commission has announced a list of major engineering projects for 2026, which includes 184 officially planned projects across various sectors, with a total investment target of 255 billion yuan, marking a historical high [1] Group 1: Project Categories - The 184 major projects are categorized into several sectors: 62 in technology and industry, 29 in social welfare, 13 in ecological civilization, 68 in urban infrastructure, and 12 in rural integration and revitalization [1] - There are also 14 planned preparatory projects for 2026 [1] Group 2: Project Status - Among the 184 projects, 16 are planned to commence construction, 22 are expected to be completed, and 168 are currently under construction [1] - Notable projects include the establishment of a national deep-sea long-term scientific observation system and various research and development bases in the technology sector [1] Group 3: Investment Details - The annual investment plan for 2026 is set at 255 billion yuan, which is a record high for the city [1] - The technology sector projects include significant initiatives such as the Shanghai hard X-ray free electron laser facility and key physical technology projects for magnetic-inertial confinement fusion energy systems [1]

Core Viewpoint - The company, 美好医疗, is experiencing growth in its medical device sector, with a focus on brain-machine interface collaborations and weight loss products, while benefiting from the depreciation of the Chinese yuan. Group 1: Company Performance - 美好医疗's stock increased by 2.35% with a trading volume of 343 million yuan and a market capitalization of 18.619 billion yuan [1] - The company reported a revenue of 1.194 billion yuan for the first nine months of 2025, representing a year-on-year growth of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [7][8] - The company has distributed a total of 293 million yuan in dividends since its A-share listing [9] Group 2: Business Operations - The company is engaged in the design, development, manufacturing, and sales of precision components and products in the medical device sector, with major products including home respiratory machine components and cochlear implant components [2][7] - 美好医疗's overseas revenue accounted for 86.64% of total revenue, benefiting from the depreciation of the yuan [3] - The company is collaborating with brain-machine interface clients to facilitate efficient commercialization from laboratory research to mass production, although current revenue from this segment is small [2] Group 3: Market Position and Shareholder Information - The company has a diverse shareholder base, with 29,800 shareholders as of January 30, 2025, and an average of 12,536 circulating shares per person [7] - Major shareholders include 国泰聚信价值优势灵活配置混合A and 华宝中证医疗ETF, with some new institutional investors entering the top shareholder list [9]

Core Insights - Becton Dickinson and Co. (BDX) is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents, operating through three segments: BD Medical, BD Life Sciences, and BD Interventional [1] Financial Performance - On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159, aimed at making shares more affordable [2][4] - BDX reported first-quarter 2026 adjusted earnings of $2.91 per share, exceeding the consensus estimate of $2.81, with sales reaching $5.25 billion, slightly above the expected $5.15 billion [2][4] Strategic Changes - BDX is undergoing significant changes, including the separation of its Biosciences and Diagnostic Solutions businesses and a combination with Waters Corporation [3] - The company has lowered its fiscal 2026 adjusted earnings guidance from a range of $14.75-$15.05 per share to $12.35-$12.65 per share, compared to the consensus of $14.72, indicating a transition year according to RBC Capital Markets [3] Stock Performance - BDX's stock is currently priced at $180.62, reflecting an increase of 5.21% or $8.94, with fluctuations between a low of $170.67 and a high of $181.98 during the trading day [3] - Over the past year, BDX has reached a high of $185.02 and a low of $127.59, with a market capitalization of approximately $51.44 billion and a trading volume of 4,441,319 shares on the NYSE [3]

Group 1: Company Listings and Developments - 澜起科技 successfully listed on the Hong Kong Stock Exchange on February 9, becoming one of the few global suppliers offering a complete range of memory solutions from DDR2 to DDR5 [1] - 极物思维 submitted its IPO application to the Hong Kong Stock Exchange, marking a new phase in its capital development [2] - 麦得发 completed its Series B financing round, with funds aimed at R&D and market expansion of PHA biodegradable materials [6] Group 2: Product Innovations and Recognitions - 真健康's four products were included in the 11th batch of the "Excellent Domestic Medical Equipment Product Directory," marking a significant recognition for its innovative surgical navigation systems [3] - 一微科技 ranked 436th in the "2025 China Enterprise Patent Strength 500" list, showcasing its strong patent capabilities in the robotics sector [4] - 一微科技 has applied for over 2000 intellectual property rights, focusing on core technologies in robotics and AI [5] Group 3: Market and Regional Developments - 极物思维 aims to strengthen its headquarters' functions and regional collaboration, positioning 横琴 as a hub connecting national store networks and capital markets [2] - 大横琴星文旅公司 launched a cross-border flower market event, introducing a new service model for flower purchases between 横琴 and 澳门 [7]

股票近期走势 经济观察网2026年2月5日，根据香港联交所披露，瑛泰医疗大股东柯伟于1月22日场外增持247万股H股 股份，均价26.0港元，总值约6,422万港元。增持后，柯伟持股比例从5.82%升至6.13%。此次增持可能 反映内部对公司长期价值的信心。 2月12日资金总净流入233.78万港元，主要为散户资金推动；技术指标如MACD显示短期弱势，KDJ处 于超卖区域，股价接近布林带下轨。 近7日(2026年2月5日至12日)瑛泰医疗股价震荡调整，区间跌幅5.88%，最新价报30.10港元(2月12日收 盘)。单日走势方面，2月5日跌3.06%，2月12日跌2.27%，整体弱于所属医疗设备板块(同期涨1.27%)及 恒生指数(跌1.01%)。 以上内容基于公开资料整理，不构成投资建议。 资金面与技术面 ...

Financial Data and Key Metrics Changes - Fourth quarter revenue increased by 12% to $269 million, while full year revenue rose by 14% to $912 million, primarily driven by growth at existing centers and new center additions [18] - Fourth quarter net income per diluted share increased by $3.51 to $4.66, and full year net income per diluted share increased by $3.09 to $4.89 [18] - Fourth quarter adjusted net income per diluted share increased by $0.51 to $1.65, and full year adjusted net income per diluted share increased by $0.80 to $2.42 [19] - Operating cash flow for the fourth quarter was $52 million, totaling $117 million for the full year [19] - The company ended the quarter with $405 million in cash and investments, allowing for continued investments in profitable growth [19] Business Line Data and Key Metrics Changes - The Inspire 5 system demonstrated superiority over Inspire 4, with a significant reduction in surgical time and improved inspiratory overlap, leading to a 79.5% responder rate in the Singapore study [11] - Approximately 10,000 Inspire 5 procedures were performed in 2025, providing a basis for professional reimbursement [9] - The company is nearing completion of manufacturing the Inspire 4 systems but has sufficient inventory for centers that may continue using it [9] Market Data and Key Metrics Changes - The company is actively engaging with key government agencies and physician societies regarding the coding of the Inspire 5 procedure, transitioning to CPT code 64582 with a -52 modifier [6][7] - The coding landscape is expected to impact physician willingness to perform the Inspire 5 procedure, potentially limiting the number of cases [8] - The WISeR program, requiring prior authorization for Medicare cases in six pilot states, has affected procedures in the first quarter [13][14] Company Strategy and Development Direction - The company plans to focus on short and long-term initiatives to address reimbursement challenges and drive consistency across the country [8] - A new CPT code is being pursued for long-term reimbursement clarity, with the goal of minimizing reductions associated with the -52 modifier [10][32] - The company aims to enhance patient access to Inspire therapy through training advanced practice providers and certifying additional surgeons [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Inspire 5 system's effectiveness and the ability to work with payers to minimize reimbursement reductions [10][102] - The company revised its full year revenue guidance for 2026 to a range of $950 million to $1 billion, reflecting expected impacts from coding uncertainty [20] - Management anticipates sequential improvement in revenue and net income throughout 2026, with the fourth quarter expected to have the highest levels of revenue and profit [24] Other Important Information - The company received FDA approval for 3 Tesla MRI compatibility, enhancing the product's appeal [14] - The Inspire 6 product development program will include features for sleep detection and auto activation, aimed at maximizing therapy adherence [15] Q&A Session Summary Question: Clarity on physician fee with Gen 5 using the 82 code and -52 modifier - Management indicated that clarity on the physician fee is expected as they work with MACs and commercial payers to drive consistency [30] Question: Pathway forward for Gen 5 and pursuing a dedicated code - Management confirmed the pursuit of a new CPT code, emphasizing that the -52 modifier is not a long-term solution [32] Question: Specifics on revenue guidance revision related to reimbursement landscape - Management clarified that the primary reason for revenue reduction is coding uncertainty, with the WISeR program causing some disruption [38] Question: Feedback from physicians regarding the -52 modifier - Management noted that most physicians are in private practice, and those in academic centers are less impacted by the fee reduction [40] Question: Impact of the WISeR program on procedures - Management acknowledged the challenges posed by the WISeR program but expressed confidence in their centers' preparedness for audits [90] Question: Expectations for commercial payers and coding transitions - Management indicated that while commercial payers currently allow billing under 64568, they expect a transition to 64582 with the -52 modifier over time [73]

Financial Data and Key Metrics Changes - Fourth quarter revenue increased by 12% to $269 million, while full year revenue rose by 14% to $912 million, primarily driven by growth at existing centers and new center additions [16] - Fourth quarter net income per diluted share increased by $3.51 to $4.66, and full year net income per diluted share increased by $3.09 to $4.89 [16] - Fourth quarter adjusted net income per diluted share increased by $0.51 to $1.65, and full year adjusted net income per diluted share increased by $0.80 to $2.42 [17] - Operating cash flow for the fourth quarter was $52 million, totaling $117 million for the full year [17] - The company ended the quarter with $405 million in cash and investments, allowing for continued investments to drive profitable growth [17] Business Line Data and Key Metrics Changes - The Inspire 5 system demonstrated superiority over Inspire 4, with a significant reduction in surgical time and improved inspiratory overlap, leading to a 79.5% responder rate in the Singapore study [9][10] - Approximately 10,000 Inspire 5 procedures were performed in 2025, providing a basis for professional reimbursement [7] - The professional fee for CPT code 64568 is approximately 10% less than the reimbursement for CPT code 64582 used for Inspire 4 procedures [7] Market Data and Key Metrics Changes - The company is actively engaging with key government agencies and physician societies regarding the coding of the Inspire 5 procedure, with expectations of transitioning to CPT code 64582 with a -52 modifier [4][5] - The WISeR program, requiring prior authorization of Medicare cases in six pilot states, has begun affecting Medicare patient procedures in the first quarter [12] Company Strategy and Development Direction - The company is focused on developing a new CPT code for the Inspire 5 procedure, with clarity on coding and reimbursement expected to enhance patient care [8][13] - The strategy includes training advanced practice providers, certifying additional surgeons, and driving the adoption of Sleep Sync and digital tools to enhance patient access to Inspire therapy [14] - The company plans to transition the existing Inspire 4 IPG line to Inspire 5 later in 2026, ensuring stable product inventory throughout 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the coding of the Inspire 5 procedure and the potential impact on physician willingness to perform the procedure due to reduced professional fees [6] - The company revised its full year revenue guidance for 2026 to a range of $950 million to $1 billion, reflecting the expected impact from coding uncertainty [18] - Management expressed confidence in the long-term growth potential and the strategies in place to drive stakeholder value [15] Other Important Information - The company completed $50 million in share repurchases during the fourth quarter, totaling $175 million for the full year [17] - The company received FDA approval for 3 Tesla MRI compatibility, enhancing the product's appeal [12] Q&A Session Summary Question: What is the expected clarity on the physician fee with Gen 5 using the 82 code and the -52 modifier? - Management indicated that clarity will come as they work with MACs and commercial payers to minimize the reduction in professional fees [25] Question: What is the pathway forward for Gen 5 and the pursuit of a dedicated code? - Management confirmed the pursuit of a new CPT code, emphasizing that the -52 modifier is not a long-term solution [27] Question: How does the WISeR program impact revenue guidance? - Management clarified that the primary reason for revenue reduction is the coding uncertainty, with the WISeR program causing some disruption but not the main issue [29] Question: What percentage of physicians are salary-based versus RVUs? - Management noted that a majority of physicians are in private practice, with academic centers being salary-based, which mitigates the impact of professional fee reductions [32] Question: How does the company plan to manage the impact of the WISeR program? - Management expressed confidence in their ability to navigate the challenges posed by the WISeR program due to their history of working with Medicare [54]

经济观察网 TD Cowen于2026年02月10日首予直觉外科公司买入评级，目标价660美元，认为公司增长 前景积极。同期，中金公司（601995）于2026年02月05日发布报告，维持中性评级，目标价531美元， 指出当前股价或已部分反映基本面预期。 财报分析 直觉外科2025年业绩好于预期，收入达100.65亿美元，同比增长20.5%，归母净利润28.56亿美元，同比 增长23.0%，主要受第五代达芬奇手术机器人（dV5）装机量放量驱动。公司预计2026年手术量增速为 13%-15%，非GAAP毛利率指引为67%-68%。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势 近7个交易日（2026年02月05日至11日），直觉外科股价区间上涨2.88%，最新报492.28美元，但年初至 今累计下跌13.08%，同期美股医疗设备板块下跌0.34%。 近期事件 2026年01月26日，公司公告dV5获FDA批准基于非力反馈耗材开展特定心脏领域手术，拓展了手术机器 人应用范畴。 ...